By diversifying its portfolio into Alzheimers with Kisunla and maintaining a lead in the breast cancer space with Verzenio (NYSE: LLY), the company has built a multi-pillared growth engine that is less reliant on a single drug class than its Danish rival
They are prepared by pharmacists rather than manufactured in FDA-inspected industrial facilities (FDA, 2024)
TrimRx emphasizes that waiting only delays results that could already be happening
Moreover, LIRA significantly suppressed the expression of proinflammatory and profibrotic biomarkers, including NF-B, CD68, IL-1, TGF-1, osteopontin, and nitrotyrosine, in comparison to vehicle-treated rats [66]
View Our Interactive Dashboard on GLP-1RA Therapies in Development (Free Excel Available) Lilly, Hanmi work on triple agonists